Incidence, Risk Factors, and Prognosis of Patients with Hepatocellular Carcinoma and Brain Metastases

Abstract

Objective

Brain metastases significantly impact the clinical course of patients with hepatocellular carcinoma (HCC). This study aimed to examine the age-related incidence, demographics, and survival of patients with HCC and brain metastases.

Methods

Data of HCC patients from 2010 to 2015 in the Surveillance, Epidemiology, and End Results (SEER) Registry were screened for the presence of brain metastases. They were stratified by age and ethnicity. Multivariable logistic and Cox regression analyses were used to identify factors associated with brain metastases and those with overall survival (OS) and liver cancer-specific survival (CSS), respectively.

Results

A total of 141 HCC patients presenting with brain metastases were identified, accounting for 0.35% of all HCC patients and 2.37% of patients with metastatic disease. Among all HCC patients, the incidence rate was the highest among patients aged 30–49 years old (0.47%). Ethnicity was not associated with the presence of brain metastases at the time of HCC diagnosis. However, African-American patients presented with a significantly lower disease-specific survival [median time: 1 month; interquartile range (IQR): 0–3.0 months)]. Initial lung or bone metastasis was independently associated with an increased risk of the presence of brain metastases [odds ratio (OR): 12.62, 95% confidence interval (CI): 8.40–18.97] but was not associated with a worse OS or CSS among those with brain metastases.

Conclusion

This study identified the age-related incidence and risk factors of brain metastases in HCC patients. These results may contribute to the consideration of brain screening among patients with initial metastatic HCC with lung or bone metastases, and influence the counseling of this patient population regarding their prognosis.

Keywords

brain metastases / hepatocellular carcinoma / age-related incidence / cancer-specific survival / overall survival

References

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015,65(2):87–108
[2]	Parkin DM, Ferlay J, Curado MP, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer, 2010,127(12):2918–2927
[3]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017,67(1):7–30
[4]	Kim M, Na DL, Park SH, et al. Nervous system involvement by metastatic hepatocellular carcinoma. J Neurooncol, 1998,36(1):85–90
[5]	Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol, 2002,249(10):1357–1369
[6]	Wang S, Wang A, Lin J, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget, 2017,8(15):25814–25829
[7]	Shao YY, Lu LC, Cheng AL, et al. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist, 2011,16(1):82–86
[8]	Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol, 2005,20(11):1781–1787
[9]	Jiang W, Zeng ZC. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma? Oncology, 2013, 84(Suppl 1):69–74
[10]	Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract, 2014,68(7):890–899
[11]	Chen SF, Tsai NW, Lui CC, et al. Hepatocellular carcinoma presenting as nervous system involvement. Eur J Neurol, 2007,14(4):408–412
[12]	Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol, 2017,19(11):1511–1521
[13]	Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol, 2009,91(3):307–313
[14]	Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer, 2011,117(19):4475–4483
[15]	Jiang XB, Ke C, Zhang GH, et al. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors. BMC Cancer, 2012,12:49
[16]	Surveillance E, and End Results (SEER) Program Research Data (1975–2015), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2018, based on the November 2017 submission. http://www.seer.cancer.gov
[17]	National Cancer Institute at the National Institutes of Health. Accessed April 30. https://www.cancer.gov/about-cancer/causes-prevention/risk/age
[18]	Namieno T, Kawata A, Sato N, et al. Age-related, different clinicopathologic features of hepatocellular carcinoma patients. Ann Surg, 1995,221(3):308–314
[19]	Han MS MK, Lee KH, et al. Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. BMC Cancer, 2013,13:567
[20]	Jones PD, Diaz C, Wang D, et al. The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population. Dig Dis Sci, 2018,63(2):515–528
[21]	Sloane D CH, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc, 2006,98(12):1934–1939
[22]	Ha J YM, Aguilar M, et al. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies. J Clin Gastroentero, 2016,50(5):423–430
[23]	Estevez J, Yang JD, Leong J, et al. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol, 2019,114(1):80–88
[24]	Yamakawa Y, Moriguchi M, Aramaki T, et al. Brain metastasis from hepatocellular carcinoma: The impact of radiotherapy on control of intracranial hemorrhage. Hepatol Res, 2015,45(11):1071–1075
[25]	Han JH, Kim DG, Chung HT, et al. Stereotactic radiosurgery for brain metastases from hepatocellular carcinoma. J Neurooncol, 2013,115(1):45–51
[26]	Park Y, Kim KS, Kim K, et al. Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study. J Neurooncol, 2015,125(2):377–383